Carregant...
Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study
BACKGROUND: This study aimed to evaluate the efficacy and safety of apatinib with a low dose of 250 mg/d in the treatment of platinum‐resistant or platinum‐refractory ovarian cancer patients. METHODS: Patients with platinum‐resistant or platinum‐refractory ovarian carcinoma treated with 250 mg/d apa...
Guardat en:
| Publicat a: | Cancer Med |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7433830/ https://ncbi.nlm.nih.gov/pubmed/32627959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3282 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|